ATRS Antares Pharma Inc.

4.82
-0.07  -1%
Previous Close 4.89
Open 4.89
Price To Book 17.85
Market Cap 786,749,749
Shares 163,226,089
Volume 1,303,341
Short Ratio
Av. Daily Volume 1,781,786
Stock charts supplied by TradingView

NewsSee all news

  1. Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    EWING, N.J., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare

  2. Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    EWING, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. ("Idorsia") (SIX: IDIA) to

  3. Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel

    • The companies will develop a novel drug-device product combining Idorsia's P2Y12 receptor antagonist, selatogrel, with the Antares QuickShot® auto-injector • Idorsia is preparing for a Phase 3 study to

  4. Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

    EWING, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare

  5. Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $34.3 Million – Earnings Per Share of $0.01 The Company Increases Full Year 2019 Revenue Guidance to a Range of $115.0 to $120.0 Million EWING, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved December 8, 2011.
Anturol
Overactive bladder
Approved Oct 14, 2013.
OTREXUP
Rheumatoid arthritis (RA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
FDA Approval announced October 1, 2018.
XYOSTED (testosterone enanthate)
Testosterone deficiency
Phase 2 trial planned for 2020.
Selatogrel and QuickShot
Acute myocardial infarction (AMI)

Latest News

  1. Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    EWING, N.J., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare

  2. Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    EWING, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. ("Idorsia") (SIX: IDIA) to

  3. Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel

    • The companies will develop a novel drug-device product combining Idorsia's P2Y12 receptor antagonist, selatogrel, with the Antares QuickShot® auto-injector • Idorsia is preparing for a Phase 3 study to

  4. Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

    EWING, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare

  5. Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $34.3 Million – Earnings Per Share of $0.01 The Company Increases Full Year 2019 Revenue Guidance to a Range of $115.0 to $120.0 Million EWING, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --

  6. Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System

    EWING, N.J., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares" or "Company") today announced that it has received the final payment of $2.5 million from Ferring Pharmaceuticals ("Ferring")

  7. Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    EWING, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare